肿瘤萌芽在多种癌症尤其是结肠直肠癌中是一种有前途的预后指标。然而，在喉鳞状细胞癌评估和验证其预后价值的研究很少，其中没有使用泛细胞角蛋白免疫组织化学方法。考虑到喉鳞状细胞癌治疗成果的平庸，需要新的预后指标变得至关重要。研究目的：我们旨在通过血染色素和伊红染色以及泛细胞角蛋白免疫组织化学方法评估喉鳞状细胞癌的肿瘤萌芽。材料和方法：回顾性研究，研究来自Ain Shams University Specialized Hospital和Ain Shams University Hospitals的2014年1月至2017年1月的118例喉鳞状细胞癌患者的病理记录。 ENT和组织病理学报告进行审核，以确定患者的临床病理数据。肿瘤萌芽与喉癌重要临床病理参数（部位、分级、肿瘤分期、淋巴结分期、淋巴结包膜外侵犯和血管侵犯）显示高度统计学显著关系（每个p = 0.0001）。肿瘤萌芽的程度与总生存率、局部复发无病生存率和远处转移无病生存率相关（每个p = 0.001）。多元分析显示，肿瘤萌芽是影响无进展生存的独立预后因素。在研究中，H&E和泛细胞角蛋白免疫组织化学检测萌芽之间存在中等一致性（kappa = 0.593）。肿瘤萌芽与喉鳞状细胞癌的不良预后临床病理指标相关。建议使用泛细胞角蛋白免疫组织化学方法评估喉鳞状细胞癌中的肿瘤萌芽，尤其是在疑难情况下。 版权所有 ©2020 Nermine M. Abd Raboh等人。

Tumor budding is a promising prognostic indicator in several cancers especially in colorectal cancer. However, only few studies have been conducted to assess and validate its prognostic value in laryngeal squamous cell carcinoma; none of which used pancytokeratin immunohistochemistry. In view of the modest results of treatment of laryngeal squamous cell carcinoma, the need of new prognostic indicators becomes of paramount importance. Aim of the Study. We aim to evaluate tumor budding in laryngeal squamous cell carcinoma, by haematoxylin and eosin, as well as by pancytokeratin immunohistochemistry. Material and Methods. A retrospective study on 118 cases of laryngeal squamous cell carcinoma from archives of Pathology Lab of Ain Shams University Specialized Hospital and Ain Shams University Hospitals from January 2014 to January 2017. The ENT and histopathology reports were reviewed to determine clinicopathologic data of the patients.Tumor budding shows high statistically significant relations (p = 0.0001 for each) with important clinicopathological parameters of laryngeal carcinoma (site, grade, tumor stage, lymph node stage, lymph node extracapsular invasion, and vascular invasion). The extent of tumor budding correlated with overall survival, local recurrence disease free, and distant metastasis disease free (p = 0.001 for each). Multivariate analysis showed tumor budding to be an independent prognostic factor affecting progression-free survival. There was a moderate agreement between H&E and IHC by pancytokeratin as regards detection of budding among study cases (kappa = 0.593).Tumor budding was correlated with poor prognostic clinicopathologic indicators in laryngeal squamous cell carcinoma. It is recommended to use pancytokeratin immunohistochemistry to evaluate tumor budding in laryngeal squamous cell carcinoma especially in confusing cases.Copyright © 2020 Nermine M. Abd Raboh et al.